Therma Bright Adds Strategic Advisor, Too Jae Min, Professor, Department of Anesthesiology and Pain Medicine, Korea University
Toronto, Ontario--(Newsfile Corp. - September 17, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright", "Therma", or the "Company"- formerly The Jenex Corporation), a progressive medical device technology company, today is pleased to announce the appointment of Dr. Too Jae Min, Professor, Department of Anesthesiology and Pain Medicine, Korea University.
Therma Adds Advisory Board Member Dr. Too Jae Min:
Dr. Too Jae Min has over 18 years experience in both academia and the business world acting as CEO of medical device and cosmetic companies. Dr. Min is currently, Professor, Department of Anesthesiology and Pain Medicine at Korea University Medical School. Dr. Min is a member of both the American and Korean Society of Anesthesiologists. Dr. Min is a member of the Medical Device Standard Development Committee in Korea and has co-authored over 50 peer reviewed publications for which he has received over 5000 citations.
Dr. Min has been awarded multiple prizes in his scientific field including: Dong-Soong Best Scientist Award (2011), Best Anesthesia and Pain Medicine article of year (2016), and Best Artificial Intelligence application in the medical field (2018).
Dr. Min received his Ph.D. in Medical Science, Graduate School of Korea University, Seoul, Korea in 2010 and his postgraduate from the Business School of Korea University (Advanced Management Program) during February 2018.
Dr. Min's role with Therma Bright will be to focus on the advancement of Therma's pain relief device and other cosmetic applications which may incorporate artificial intelligence("AI") for Therma Bright's technology platform.
Rob Fia, CEO, Therma Bright Inc. comments:
"Therma is pleased to add Dr. Min to our advisory board. Dr. Min's experience in both academia and the business world will assist Therma via collaboration with industry leading medical device researchers and manufacturers in Korea to develop our unique pain relief device and other medical devices. Therma may incorporate AI and other features through Dr. Min's expertise in this area. We look forward to drawing on Dr. Min's expertise and extensive contact base in the Korean medical device market to enhance our existing medical devices to create new devices and technologies."
Therma Bright also announces that it has granted incentive stock options to certain directors, officers and consultants of the Company to purchase up to an aggregate of 250,000 common shares of the Company pursuant to the Company's share option plan. The options will vest after 6 months and are exercisable for a period of five years at a price of $0.05/share.
Therma Bright has a wide range of experts at its disposal, including Advisory Board members, that will advise on developing Therma Bright's thermal therapy technology. In addition, Therma Bright has experts that can be referred to that have established relationships to market its technology and to research and develop its technology platform through scientific experts specializing in the advancement of the Company's broadening technology platform. The Company expects to provide a number of updates on the development of its pain relief device, its insect device, TherOZap™ and further testing of the technology against the Zika virus, and its InterceptCS™ in the near future.
Therma is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Therma's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary technology delivers effective, cost-effective, non-invasive and pain free skin care.
Therma received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Therma received approval for the above claims from FDA (United States) in 1997.
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events or the Company's future performance and include the Pain Relief, Activators and Zika Tests and the Company's thermal therapy technology, developing new devices and technology, all as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company may not complete the purchase of or commercialization or marketing of the Proposed Acquisitions or research and development of new devices or technology as described in this news on the timelines described and the Company may not attract a financing in the future. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
For further information please contact:
Therma Bright Inc.
NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES